Utilizing precision medicine to treat alcohol use disorder: A commentary on the α1 receptor antagonist
- PMID: 36852535
- PMCID: PMC10050091
- DOI: 10.1111/acer.15014
Utilizing precision medicine to treat alcohol use disorder: A commentary on the α1 receptor antagonist
Conflict of interest statement
Conflicts of Interest
The author has nothing to disclose.
Comment on
-
A randomized controlled clinical trial of prazosin for alcohol use disorder in active duty soldiers: Predictive effects of elevated cardiovascular parameters.Alcohol Clin Exp Res (Hoboken). 2023 Feb;47(2):348-360. doi: 10.1111/acer.14989. Epub 2023 Feb 21. Alcohol Clin Exp Res (Hoboken). 2023. PMID: 36809662 Clinical Trial.
References
-
- ASTON-JONES G, SHIPLEY M, CHOUVET G, ENNIS M, VAN BOCKSTAELE E, PIERIBONE V, SHIEKHATTAR R, AKAOKA H, DROLET G & ASTIER B 1991. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Progress in brain research, 88, 47–75. - PubMed
-
- HAASS-KOFFLER CL, GOODYEAR K, ZYWIAK WH, MAGILL M, ELTINGE SE, WALLACE PM, LONG VM, JAYARAM-LINDSTROM N, SWIFT RM, KENNA GA & LEGGIO L 2017. Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin. Drug Alcohol Depend, 177, 23–28. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical